LITTLETON, Mass.--(BUSINESS WIRE)--At the first virtual meeting of the American Society for Radiation Oncology (ASTRO) 2020 Annual Meeting, October 23rd to the 29th, Mevion will highlight its research and development progress demonstrating the FLASH effect on commercially available MEVION S250i compact proton accelerators.

FLASH Therapy*, a non-invasive, ultra-high dose rate delivered at incredible speeds, may dramatically improve the cancer-fighting benefits of therapeutic radiation by shortening treatment courses and lessening side effects. Driven by innovation and guided by a coalition of clinical partners and FLASH thought leaders, Mevion’s Advanced Development team has yielded strong results from an initial small animal study that could propel this potentially promising cancer treatment forward.

“The initial results from our study conducted this summer on a commercial production accelerator produced very promising results and a FLASH effect at the Bragg Peak,” said Townsend Zwart, Ph.D. vice president, Advanced Development at Mevion. “Our MEVION S250i accelerator is a powerful and robust system, inherently capable of delivering the ultra-high dose rates at ultra-high speeds needed for FLASH on a platform that will make it easier and simpler for centers to study the potentially revolutionary effects of FLASH Therapy without modifications to the accelerator or shielding.”

MEVION S250i accelerators have a particularly high intra-pulse dose rate. A high intra-pulse dose rate has been associated, in previous clinical experience, as a key to a consistent FLASH effect. The study and its results will be presented during the annual meeting on Tuesday, October 27, at 11:45 AM in the Innovation Hub.

Image-Guided Positioning Suite
A range of natively integrated imaging and patient positioning options are now available on Mevion systems. While other proton manufacturers provide a locked-in solution built into their system, Mevion proton systems are designed with a unique open architecture to keep centers imaging and positioning solutions current with the future advancements and evolution in IGPT. Customizable solutions from best-in-class providers such as medPhoton, Siemens®, and Stryker Spine for 3D imaging, C-Rad™, and DYN’R® provide surface tracking and motion management, and CIVCO Radiotherapy, Orfit®, and Qfix™ enable precise patient positioning and immobilization, allowing centers to configure the best solution to meet their needs.

Demonstrations
Mevion will provide treatment planning demonstrations at the Mevion booth that will feature the latest capabilities and clinical performance of the HYPERSCAN® Pencil Beam Scanning System in conjunction with the treatment planning system RayStation®. Raystation’s recent 10A upgrade provides significant improvements to the HYPERSCAN treatment planning experience that enables superior plans to be generated in as little as 5 minutes.

In addition, Mevion will be providing live architectural demonstrations for attendees to visualize how a proton system could be integrated into their center.

ASTRO attendees are invited to visit the Mevion virtual booth to talk to our team about Mevion proton therapy solutions, FLASH Therapy progress, IGPT customizations, and to learn more about how Mevion has changed proton therapy.


About Mevion Medical Systems
Since 2004, Mevion Medical Systems has been the leading provider of compact proton therapy systems for cancer care. Dedicated to advancing the design and accessibility of proton therapy worldwide, Mevion was the first company to innovate this new single-room platform and continues to further the science and application of proton therapy. Mevion’s flagship product, the MEVION S250i Proton Therapy System with HYPERSCAN pencil beam scanning, is the world’s smallest proton therapy system that eliminates the obstacles of size, complexity, and cost that exists with other proton therapy systems. Mevion is headquartered in Littleton, Massachusetts, with a presence in Europe and Asia.